Unknown

Dataset Information

0

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.


ABSTRACT: Epidermal growth factor receptor (EGFR) over-signaling leads to more aggressive tumor growth. The antitumor effect of Cetuximab, an anti-EGFR antibody, depends on oncogenic-signal blockade leading to tumor cell apoptosis and antibody dependent cell-mediated cytotoxicity (ADCC). However, whether adaptive immunity plays a role in Cetuximab-mediated tumor inhibition is unclear, as current xenograft models lack adaptive immunity and human-EGFR-dependent mouse tumor cell lines are unavailable. Using a newly developed xenograft model with reconstituted immune cells, we demonstrate that the Cetuximab effect becomes more pronounced and reduces the EGFR(+) human tumor burden when adaptive immunity is present. To further study this in a mouse tumor model, we created a novel EGFR(+) mouse tumor cell line and demonstrated that Cetuximab-induced tumor regression depends on both innate and adaptive immunity components, including CD8(+) T cells, MyD88, and Fc?R. To test whether strong innate signals inside tumor tissues amplifies the Cetuximab-mediated therapeutic effect, Cetuximab was conjugated to CpG. This conjugate is more potent than Cetuximab alone for complete tumor regression and resistance to tumor rechallenge. Furthermore, Cetuximab-CpG conjugates can activate tumor-reactive T cells for tumor regression by increasing dendritic cell (DC) cross-presentation. Therefore, this study establishes new models to evaluate immune responses induced by antibody-based treatment, defines molecular mechanisms, and provides new tumor-regression strategies.

SUBMITTER: Yang X 

PROVIDER: S-EPMC3538305 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

Yang Xuanming X   Zhang Xunmin X   Mortenson Eric D ED   Radkevich-Brown Olga O   Wang Yang Y   Fu Yang-Xin YX  

Molecular therapy : the journal of the American Society of Gene Therapy 20120918 1


Epidermal growth factor receptor (EGFR) over-signaling leads to more aggressive tumor growth. The antitumor effect of Cetuximab, an anti-EGFR antibody, depends on oncogenic-signal blockade leading to tumor cell apoptosis and antibody dependent cell-mediated cytotoxicity (ADCC). However, whether adaptive immunity plays a role in Cetuximab-mediated tumor inhibition is unclear, as current xenograft models lack adaptive immunity and human-EGFR-dependent mouse tumor cell lines are unavailable. Using  ...[more]

Similar Datasets

| S-EPMC3927846 | biostudies-literature
| S-EPMC8241538 | biostudies-literature
| S-EPMC6133214 | biostudies-literature
| S-EPMC5625838 | biostudies-other
| S-EPMC2435248 | biostudies-literature
| S-EPMC10557730 | biostudies-literature
| S-EPMC7832040 | biostudies-literature
| S-EPMC10512012 | biostudies-literature
| S-EPMC9459000 | biostudies-literature
| S-EPMC10721446 | biostudies-literature